INDIANAPOLIS, April 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA ® (ramucirumab). CYRAMZA ...
CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology INDIANAPOLIS, June 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that The Lancet Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results